ENEX Acquires 6.67% Stake in Financially Weak Dermato Bio: Small Investment with Put Option
ENEX has decided to acquire 34,270 shares, a 6.67% stake in Dermato Bio, by participating in a third-party allotment capital increase worth approximately 2 billion KRW.
The purpose is equity investment and business synergy creation. Dermato Bio has sustained net losses for the past three years and is in a capital impairment state, indicating very weak financial health.
The acquisition amount accounts for about 4.87% of ENEX's equity and 12.4% of its market cap, but the dilution effect on existing shareholders is limited as no new shares are issued by ENEX.
ENEX has secured a put option allowing it to demand repayment with 4% annual interest if Dermato Bio fails to achieve growth milestones such as a KOSDAQ listing within five years, partially hedging downside risk.
[AI Summary]ENEX made a small equity investment in a financially weak unlisted biotech firm but protected downside risk via a put option. The short-term stock price impact is limited, but Dermato Bio's future performance and listing outcome will be key to investment recovery.
KOSPI Filing Information
Decision on Acquisition of Stocks and Investment Securities of Other Corporations (Voluntary Disclosure)